Professor D L Scott, King's College Hospital, East Dulwich Grove, Dulwich, London SE22 8PT, UKleigh.joyce{at}kcl.ac.uk OBJECTIVE Recent studies have demonstrated the short term efficacy of leflunomide ...

Correspondence to Dr Sylvain Mathieu, Rheumatology Department, Gabriel Montpied Teaching Hospital, 63003 Clermont-Ferrand, France; smathieu{at}chu-clermontferrand.fr We searched PubMed to find reports ...

To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set ...

When a year closes and gives way to its successor, it is good to pause for breath to reflect on the achievements of the past and contemplate the prospects for the incoming year. So when looking back ...

Objective: To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With recent therapeutic advances, this is now a goal for treatment and may represent a measure to compare ...

Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, France Dr M De Bandt, Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, 93600, France; m.debandt{at}ch-aulnay.fr ...

Background: Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes the development of radiographic sacroiliitis, ...

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid ...

1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...

Correspondence to Dr David T Ewart, Division of Rheumatic and Autoimmune Diseases, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA; ewar0001{at}umn.edu and ...

Objectives: To compare the efficacy and tolerability of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day used to attain a target serum urate concentration (sUr) ⩽0.30 mmol/l (5 mg/dl).

Over the past decades, the concept of ‘remission’ has emerged as a moniker for the disease state one would ideally like to achieve when a ‘cure’—the ultimate goal of medical intervention—cannot ...